Abstract
Importance of the field: The emergence of resistance in treatment-experienced HIV patients often limits therapeutic success of the currently available antiretroviral drugs. New drug classes are thus required. Maraviroc is the first chemokine receptor 5 antagonist approved for use in treatment experienced HIV patients with a R5-tropic virus. Areas covered in this review: For this review, data from pharmacokinetic, Phase II and III clinical trials were reviewed. What the reader will gain: The objectives of this review were to discuss the pharmacokinetics and clinical efficacy and safety of maraviroc in treatment-experienced and -naive HIV patients with R5-tropic virus. Additionally, tropism testing was discussed. Take home message: Maraviroc is effective in previously treated patients with R5-tropic virus only. Also, maraviroc will be an attractive option for HIV-1-infected treatment-naive patients with R5-tropic viruses only, once genotypic assays have been validated.
| Original language | English |
|---|---|
| Pages (from-to) | 1215-1223 |
| Number of pages | 9 |
| Journal | Expert Opinion on Pharmacotherapy |
| Volume | 11 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - May 2010 |
| Externally published | Yes |
Keywords
- Antiretroviral therapy
- CCR5 antagonist
- HIV
- Maraviroc
Fingerprint
Dive into the research topics of 'Treatment of HIV infection with the CCR5 antagonist maraviroc'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver